CEO, Q-Sera
| Role | Organisation | Sources |
|---|---|---|
| CEO | Q-Sera | Uniseed |
Stories naming Michael Grant. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Q-Sera's rapid-clotting blood tube technology has gone to market in Japan via Terumo's VenoJect II launch; the Melbourne startup's backers include MRCF, Uniseed and the UniQuest Extension Fund.